Syndax Pharmaceuticals
SNDX
SNDX
245 hedge funds and large institutions have $2.32B invested in Syndax Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 98 increasing their positions, 68 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
7% more funds holding
Funds holding: 228 → 245 (+17)
2.28% less ownership
Funds ownership: 114.94% → 112.66% (-2.3%)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Holders
245
Holding in Top 10
10
Calls
$15.2M
Puts
$8.14M
Top Buyers
| 1 | +$82.1M | |
| 2 | +$20.9M | |
| 3 | +$15.2M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$9.71M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.5M |
Top Sellers
| 1 | -$62.9M | |
| 2 | -$26M | |
| 3 | -$15.2M | |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$14.2M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$13.2M |
